Use of laboratory and imaging investigations in dementia

Neurology in Practice

Volumn 76, Issue SUPPL. 5, 2005, Pages

  Van Der Flier, W M ^a   Scheltens, P ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PROTEIN 14 3 3; TAU PROTEIN;

BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC IMAGING; ELECTROENCEPHALOGRAPHY; GENETIC ANALYSIS; HUMAN; IMAGE ANALYSIS; LABORATORY TEST; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SYMPTOM; TEMPORAL LOBE;

DEMENTIA; ELECTROENCEPHALOGRAPHY; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROLOGIC EXAMINATION; NEUROPSYCHOLOGICAL TESTS; PSYCHIATRIC STATUS RATING SCALES;

EID: 28344446001     PISSN: 14737086     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.082149     Document Type: Review

References (26)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed (DSM IV). Washington DC: APA, 1994.
2. Knopman DS, DeKosky ST, Cummings JL, et al. Practice parameter: diagnosis of dementia (an evidence-based review): report of the quality standards subcommittee of the American Academy of Neurology. Neurology 2001;56:1143-53.
3. Hejl A, Hogh P, Waldemar G. Potentially reversible conditions in 1000 consecutive memory clinic patients. J Neurol Neurosurg Psychiatry 2002;73:390-4.
4. Petersen RC, Smith GE, Waring SC, et al. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-8.
5. Scheltens P, Fox N, Barkhof F, et al. Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol 2002;1:13-21.
6. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acfa Neuropathol (Berl) 1991;82:239-59.
7. Gosche KM, Mortimer JA, Smith CD, et al. Hippocampal volume as an index of Alzheimer neuropathology: findings from the Nun study. Neurology 2002;58:1476-82.
8. Jack CRJ, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997;49:786-94.
9. Korf ES, Wahlund LO, Visser PJ, et al. Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 2004;63:94-100.
10. Fox NC, Warrington EK, Freeborough PA, et al. Presymptomatic hippocampal atrophy in Alzheimer's disease. A longitudinal MRI study. Brain 1996;119(Pt 6):2001-7.
11. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. J Neurol Neurosurg Psychiatry 1992;55:967-72.
12. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 1998;51:1546-54.
13. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250-60.
14. Van Straaten EC, Scheltens P, Knol DL, et al. Operational definitions for the NINDS-AIREN criteria for vascular dementia. An interobserver study. Stroke 2003;34:1907-12.
15. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA 1997;277:813-17.
16. Medical Research Council CFAS Investigators. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology group or the Medical Research Council cognitive function and ageing study (MRC CFAS). Lancet 2001;357:169-75.
17. Jagust W. Molecular neuroimaging in Alzheimer's disease. NeuroRx 2004;1:206-12.
18. Shoghi-Jadid K, Small GW, Agdeppa ED, et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35.
19. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004;55:306-19.
20. Jelic V, Johansson SE, Almkvist O, et al. Quantitative electroencephalography in mild cognitive impairment: longitudinal changes and possible prediction of Alzheimer's disease. Neurobiol Aging 2000;21:533-40.
21. Claus JJ, Kwa VI, Teunisse S, et al. Slowing on quantitative spectral EEG is a marker for rate of subsequent cognitive and functional decline in early Alzheimer disease. Alzheimer Dis Assoc Disord 1998;12:167-74.
22. Zerr I, Pocchiari M, Collins S, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 2000;55:811-15.
23. Strittmatter WJ, Roses AD. Apolipoprotein E and Alzheimer disease. Proc Natl Acad Sci U S A 1995;92:4725-7.
24. Mayeux R, Sounders AM, Shea S, et al. Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers consortium on apolipoprotein E and Alzheimer's disease. N Engl J Med 1998;338:506-11.
25. Strozyk D, Blennow K, White LR, et al. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 2003;60:652-6.
26. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605-13.